CommentaryLarge-cell transformation of mycosis fungoides–differential diagnosis with implications for clinical management: A consensus statement of the US Cutaneous Lymphoma Consortium
Section snippets
The problem
The prognosis of cutaneous anaplastic large-cell lymphoma (cALCL) is excellent whereas the prognosis of LCT-MF is poor.1, 2, 3 cALCL is currently defined as a cutaneous tumor of large cells with anaplastic, pleomorphic or immunoblastic morphology that express the CD30 antigen by the majority (>75%) of tumor cells.4 According to the World Health Organization Classification of Tumors of Hematopoietic and Lymphoid Tissues, patients with primary cALCL should not have clinical evidence or a history
Toward the solution
To address the distinction of cALCL and LCT-MF, Fauconneau et al12 conducted a retrospective study of “typical” cases (32 cALCL and 34 CD30-rich LCT-MF) and a group of 15 “borderline” cases for which the diagnosis separating the 2 entities was difficult and controversial. They found that perforin expression was more frequent in cases of cALCL than in LCT-MF (53% vs 10%, P = .00065). The interferon regulatory factor 4/dual specificity phosphatase 22 translocation previously reported in 25% of
References (18)
- et al.
Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)
Blood
(2007) - et al.
Transformation of mycosis fungoides: clinicopathologic and prognostic features of 45 cases
Blood
(2000) - et al.
Primary and secondary cutaneous CD30+ lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on long-term follow-up data of 219 patients and guidelines for diagnosis and treatment
Blood
(2000) - et al.
WHO-EORTC classification for cutaneous lymphomas
Blood
(2005) - et al.
Transformation of mycosis fungoides/Sézary syndrome: clinical characteristics and prognosis
Blood
(1998) - et al.
Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases
Blood
(2012) - et al.
Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies
Mod Pathol
(2011) - et al.
IRF4 gene rearrangements define a subgroup of CD30-positive cutaneous T-cell lymphoma: a study of 54 cases
J Invest Dermatol
(2010) - et al.
The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin
Blood
(1996)
Cited by (45)
Spatially Resolved Transcriptomes of CD30+-Transformed Mycosis Fungoides and Cutaneous Anaplastic Large-Cell Lymphoma
2024, Journal of Investigative DermatologyMycosis fungoides and Sézary syndrome: focus on the current treatment scenario
2021, Anais Brasileiros de DermatologiaCitation Excerpt :The CD30 molecule may eventually be expressed in neoplastic cells, but this expression seems to be more frequent and more intense in cases that show transformation to large cell lymphoma. The transformed MF is defined by the presence of large cells (≥ 4-fold the size of a small lymphocyte) surpassing > 25% of the dermal infiltrate or presenting microscopic nodules and is generally associated with a worse prognosis.3 The clinical staging of MF and SS is based on the classification of cutaneous (T), lymph node (N), visceral (M) and hematological (B) involvement (Tables 2 and 3).
Differential SATB1 Expression Reveals Heterogeneity of Cutaneous T-Cell Lymphoma
2021, Journal of Investigative DermatologyCitation Excerpt :To date, no reliable criteria for distinguishing PCALCL from MF-LCT has been developed. Cytotoxic markers, microRNA dysregulation, and 6p25.3 rearrangement were found in both entities (Fauconneau et al., 2013; Kadin et al., 2014; Karai et al., 2013; Wada et al., 2011). Here, our study suggested that SATB1 and CD30 colocalization on transformed cells is a promising and feasible marker to distinguish these two entities.
Outcomes of Patients with Transformed Mycosis Fungoides: Analysis from a Prospective Multicenter US Cohort Study
2020, Clinical Lymphoma, Myeloma and LeukemiaCitation Excerpt :Although MF in its earliest stages is for most patients an indolent lymphoma, patients with tumor stage (T3) disease and tMF have a similar outcome with median survival of 19 to 36 months.8,9 The definition of LCT is based on the presence of >25% large cells or the presence of microscopic aggregates of large cells in the biopsy.6,8,13 A recent retrospective review by Talpur et al.10 of 1900 patients with MF reported an incidence of tMF of 9%.
Recent Advances in Cutaneous T-cell Lymphoma: Diagnostic and Prognostic Considerations
2019, Surgical Pathology Clinics
Funding sources: None.
Conflicts of interest: None declared.